{"name":"Affymax","slug":"affymax","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1369000,"revenueGrowth":0,"grossMargin":0,"rdSpend":11857000,"netIncome":-1059000,"cash":7443000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Epoetin alfa or Epoetin beta","genericName":"Epoetin alfa or Epoetin beta","slug":"epoetin-alfa-or-epoetin-beta","indication":"Anemia of chronic kidney disease","status":"phase_3"}]}],"pipeline":[{"name":"Epoetin alfa or Epoetin beta","genericName":"Epoetin alfa or Epoetin beta","slug":"epoetin-alfa-or-epoetin-beta","phase":"phase_3","mechanism":"Epoetin alfa/beta is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","indications":["Anemia of chronic kidney disease","Chemotherapy-induced anemia in cancer patients","Anemia in patients with HIV infection on antiretroviral therapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBQTVhLUjd0VXRRWmd4cjVabVFZN2JmSmZ5Q3pTREI1WXhfRTRBakduRUFHaXVCcEdoRFVLVU5XTDhjaUk5ck5nWDBvT3hpWHdXb05Qd1FjQ3RqXzZFOUhJanFpZDZnSU5a?oc=5","date":"2020-08-08","type":"pipeline","source":"PharmTech.com","summary":"Advancing the Peptide Pipeline - PharmTech.com","headline":"Advancing the Peptide Pipeline","sentiment":"neutral"},{"date":"2014-09-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2014-08-22","type":"earnings","source":"SEC EDGAR","summary":"SC 13D filed with SEC: SCHEDULE 13D","headline":"SC 13D Filing","sentiment":"neutral"},{"date":"2014-07-31","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPY082cEx2ZkgwUENmc0tBOXI5cVh2blBxQ0FIbFpOVTN5TGFjZjRSRzVuUF9TNTZEYTFud3hIa0F0VW9XSDRkOU1kbDd1NGVVOEs5bHRBVmNIOExSSHZ6eVRaZHA4WmpfSW80R05JSF8xWW9WS1BDeG5PclZfdGowemJwWnNhd1FaY182V2x1MA?oc=5","date":"2014-06-16","type":"pipeline","source":"PMLiVE","summary":"Omontys terminal as Takeda switches off support - PMLiVE","headline":"Omontys terminal as Takeda switches off support","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxObUoyMWVNOFZSdVVjbC1GU3gyeWlnTkMyRFF3blFWYzNZZ2YxbVNiUjUwQnVHelprM3BSWmlCNks3X1hIQ3gxclJHZzVBM2hXV1dGazhLd25VdHNWUXRLTDZOZm03ejZjaGFGRUx3SHkwUEVZV1lkSFE4Ni1zQWRiX3Y0ck9OTmND?oc=5","date":"2013-03-20","type":"pipeline","source":"PMLiVE","summary":"Affymax in a tailspin after Omontys recall - PMLiVE","headline":"Affymax in a tailspin after Omontys recall","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQQnhyVDJjTVRFZkJYdUN3czliS3p1RjVzRE91MDV1SmFDcVBMeHZEUXZMMTlVbEtCT3hmTTkwaTZ4V3FrbzhuSDRGdlI3X2VzaWdUaUlIMTdvcjFkd095X2JhRkhiRTByTFBsaGxlSE9iTnlzTDc1VldsQVhMWTBlSkgteGpabDhWTUxF?oc=5","date":"2013-02-24","type":"pipeline","source":"Fierce Pharma","summary":"UPDATED: Affymax, Takeda pull Omontys after 3 deaths - Fierce Pharma","headline":"UPDATED: Affymax, Takeda pull Omontys after 3 deaths","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1DOXlzRWxoUUhvWVBHZmFPRWZvTjRWWXFyUnhiaGJScVpEdzR1emQ0WWZrQk5ad1owcDRIcDZHaUJ3UTh3emdFMU96REhYa0oyLW1KMWJFdWtCcUgxOFAtcA?oc=5","date":"2013-01-24","type":"pipeline","source":"NEJM","summary":"Peginesatide in Patients with Anemia Undergoing Hemodialysis - NEJM","headline":"Peginesatide in Patients with Anemia Undergoing Hemodialysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE03Rnh1VHgydnVHVkQwQ3BJeV96aHhXQmxKWDdCWEo1R050S1psY0stNUVNQW13eFBidFVsdUZ6VmZNWGY4V1pwSVVvVlFsSk1rblNUWjlYc2poRWhfYUJXSA?oc=5","date":"2013-01-24","type":"pipeline","source":"NEJM","summary":"Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis - NEJM","headline":"Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNTnlrdWRZOVRaT1RqMXBPTkU1d0V6bDhZOU5DNF9ySEF3bzljVGtFV3o3QXF4NjJ0M0F1ZWo3eG1QRERGOG5BNmpIZ1RuRk42UVBBZDN0aWxFREdtSnMtaW1ZdnFFaEtRSFRDNzRoLU5ucEhjUU0yRjNic05zVGpXZWhVbC1YU0tWU3FQS2kyQjd1OXVy?oc=5","date":"2012-04-10","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Affymax Achieves $50M Milestone in Anemia Deal with Takeda - Genetic Engineering and Biotechnology News","headline":"Affymax Achieves $50M Milestone in Anemia Deal with Takeda","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":1369000,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":1369000,"period":"2013-12-31"},{"value":0,"period":"2013-12-31"},{"value":0,"period":"2013-09-30"},{"value":525000,"period":"2013-06-30"},{"value":844000,"period":"2013-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11857000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-1059000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":7443000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}